2013
DOI: 10.1016/j.redar.2012.12.003
|View full text |Cite
|
Sign up to set email alerts
|

2013. Documento Sevilla de Consenso sobre Alternativas a la Transfusión de Sangre Alogénica. Actualización del Documento Sevilla

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 64 publications
(2 citation statements)
references
References 202 publications
0
2
0
Order By: Relevance
“…According to the most recent guidelines for GIB management, a restrictive transfusion strategy is recommended (Grade 1A), 4,25,26 with a Hb threshold value of 8 g/ dl 18,27 and 7 g/dl in patients with and without heart disease, respectively. 13,25 Moreover, it is currently recommended that patients with and without heart disease maintain a Hb target range of 8-10 g/dl and 7-9 g/dl after transfusion, respectively (Grade 1A), 18,25,27,28 even during active bleeding episodes (Grade 1C). 13 In this analysis is observed a post-transfusion global median Hb value 8,8 (IQR 7,9-9,6), according to the literature.…”
Section: Discussionmentioning
confidence: 99%
“…According to the most recent guidelines for GIB management, a restrictive transfusion strategy is recommended (Grade 1A), 4,25,26 with a Hb threshold value of 8 g/ dl 18,27 and 7 g/dl in patients with and without heart disease, respectively. 13,25 Moreover, it is currently recommended that patients with and without heart disease maintain a Hb target range of 8-10 g/dl and 7-9 g/dl after transfusion, respectively (Grade 1A), 18,25,27,28 even during active bleeding episodes (Grade 1C). 13 In this analysis is observed a post-transfusion global median Hb value 8,8 (IQR 7,9-9,6), according to the literature.…”
Section: Discussionmentioning
confidence: 99%
“…[1][2][3] The therapeutic strategy for acute bleeding is mainly based on two approaches: (i) the use of predefined transfused ratios with variable combination of red cell concentrate, fresh frozen plasma and platelet concentrate (the ratio of 1:1:1 is usually associated with better outcomes) or (ii) the use of individualized goal-directed therapy, where different clusters of coagulation factors and pharmacological agents can be employed. [4][5][6][7][8] This last approach usually relies on close monitoring on clot formation and lyses by viscoelastic tests.…”
Section: Introductionmentioning
confidence: 99%